Sarepta Therapeutics reported $45.7M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Agios Pharmaceuticals USD 19.93M 3.58M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
BioCryst Pharmaceuticals USD 14.58M 3.12M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Capricor Therapeutics 3.05M 31.77K Sep/2026
Daiichi Sankyo JPY 612.24B 73.19B Sep/2026
Eli Lilly USD 5.79B 319M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
Insmed USD 84.3M 9.75M Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
Moderna USD 259M 92M Sep/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novavax USD 24.94M 2.01M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 24.55B 957M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Tectonic Therapeutic USD 1.68M 877K Jun/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026